How to read a clinical trial
The abstract is a trailer. The useful parts are who was studied, what was compared, and what was left out.
Start with the design, not the percent
A randomized trial assigns people to treatments by chance, which is the point: it balances, imperfectly, the things you didn’t measure. A placebo control asks whether the change beat doing nothing that looks like treatment. An uncontrolled series cannot answer that. Everyone might have improved anyway.
Observational studies watch what already happened. They can find associations. They cannot, alone, prove the exposure caused the outcome. Case reports are one or a few stories. They are how rare harms surface. They are not efficacy.
Population, comparator, endpoint
Who was allowed in? TRIUMPH-1, the retatrutide trial indexed here, enrolled adults with obesity and without diabetes. A result in that group is not a result in every body, and it is not a result for a research-catalog vial of uncertain identity.
What was the comparison? “Better than last month” is not a comparator. Placebo is. The primary endpoint is the outcome the trial promised to judge itself on, before the data came in. Other findings can be real and still be secondary, which means they were easier to get by chance.
Phases, in one breath
Phase 1 is usually a small safety and pharmacology study, often in healthy volunteers. Phase 2 asks whether there is a signal in patients, and at what dose. Phase 3 is the large trial meant to show that a defined product works for a defined use. Clearing phase 3 is not an approval. Approval is a regulator’s decision about a specific product, indication, and label.
STEP 1 is an example of a phase 3 trial of an already carefully defined medicine, semaglutide 2.4 mg. The numbers belong to that product. Peptarium points at the paper and does not pretend a powdered vial inherits them.
Sources for the named trials and approvals live on the compound pages and in the evidence explorer. This essay does not add new numbers.